Rupatadine Treatment Is Associated with Atherosclerosis Worsening and Altered T Lymphocyte Recruitment

Marco Busnelli; Stefano Manzini; Alice Colombo; Fabrizia Bonacina; Giuseppe D Norata; Elsa Franchi; Silvia Castiglioni; Christos Andronis; Eftychia Lekka; Eugenio Scanziani; Giulia Chiesa

doi:10.1055/a-1678-4031

Rupatadine Treatment Is Associated with Atherosclerosis Worsening and Altered T Lymphocyte Recruitment

Thromb Haemost. 2022 May;122(5):853-856. doi: 10.1055/a-1678-4031. Epub 2022 Jan 16.

Authors

Affiliations

¹ Department of Pharmacological and Biomolecular Sciences, Università degli Studi di Milano, Milano, Italy.
² Biovista, Athens, Greece.
³ Mouse and Animal Pathology Laboratory, Fondazione UniMi, Milano, Italy.
⁴ Department of Veterinary Medicine, Università degli Studi di Milano, Milano, Italy.

^# Contributed equally.

No abstract available

Publication types

Letter

MeSH terms

Atherosclerosis* / drug therapy
Cyproheptadine / analogs & derivatives
Double-Blind Method
Humans
T-Lymphocytes*

Substances

rupatadine
Cyproheptadine

Grants and funding

Funding This work was funded by the European Community's Seventh Framework Programme (FP7/2012–2017) RiskyCAD, grant no. 305739 (G.C.), “Post-Doctoral Fellowship 2021” by “Fondazione Umberto Veronesi” 2021-442 (F.B.), PRIN 2017K55HLC (G.D.N.), and by grants from MIUR Progetto Eccellenza.